As ATRX loss is found in a variety of cancer types, we aimed to assess ATRX loss in combination with dysregulation of two of the most prevalent types of oncogenic pathways—the Ras pathway and the p53 pathway—to include a large spectrum of human cancers. Here, TP53 is linked to cancer.